The latest operating income for LYEL is $130M as of June 2026. That compares with $-360M in the prior-year period — up 137.7% year over year. Investors often review this figure alongside Lyell Immunopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, LYEL's operating income moved from $-360M to $130M — a 137.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lyell Immunopharma's operating scale or balance-sheet position.

A operating income figure of $130M for LYEL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LYEL's operating income ($130M), review year-over-year change from $-360M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lyell Immunopharma's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.